Boston Scientific Contour SE Uterine Fibroid Treatment Launch Commences
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is supporting the launch of its Contour SE embolic agent for uterine fibroid treatment with trial data showing that embolized patients returned to work three times sooner than those treated with myomectomy
You may also be interested in...
Biocompatibles’ Drug-Eluting UFE Treatment Would Be Marketed By Terumo
Biocompatibles International may await development of a drug-eluting version of its Bead Block microspheres therapy before seeking FDA clearance for uterine fibroid embolization (UFE)
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.